Enhancement of cisplatin sensitivity by NSC109268 in budding yeast and human cancer cells is associated with inhibition of S-phase progression

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 5, 2010, Pages 945-952

  Jain, Dilip ^a   Patel, Nila ^a   Shelton, Melanie ^a,b   Basu, Alakananda ^a   Roque, Rouel ^a,c   Siede, Wolfram ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b JACKSON STATE UNIVERSITY   (United States)

^c TOURO UNIVERSITY NEVADA   (United States)

Author keywords

Cisplatin; Ovarian cancer; Proteasome inhibitor; Resistance; S phase; Yeast

Indexed keywords

CARBOPLATIN; CHLORMETHINE; CISPLATIN; NSC 109268; NSC 109272; PROTEASOME INHIBITOR; TRANSPLATIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MONOTHERAPY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; YEAST CELL;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; COORDINATION COMPLEXES; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; FLOW CYTOMETRY; HAPLOIDY; HUMANS; MALE; OVARIAN NEOPLASMS; PHENOTYPE; PROSTATIC NEOPLASMS; S PHASE; SACCHAROMYCES CEREVISIAE;

EID: 77956228898     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1246-8     Document Type: Article

References (32)

1. R Agarwal SB Kaye 2003 Ovarian cancer: strategies for overcoming resistance to chemotherapy Nat Rev Cancer 3 502 516 10.1038/nrc1123 1:CAS:528:DC%2BD3sXltVSqtr0%3D 12835670
2. DD Ager RH Haynes 1990 Analysis of interactions between mutagens I. Heat and ultraviolet light in Saccharomyces cerevisiae Mutat Res 232 313 326 1:CAS:528:DyaK3MXislek 2215539
3. GI Belova ON Demidov AJ Fornace Jr DV Bulavin 2005 Chemical inhibition of Wip1 phosphatase contributes to suppression of tumorigenesis Cancer Biol Ther 4 1154 1158 10.4161/cbt.4.10.2204 1:CAS:528:DC%2BD28XkvFGhu7o%3D 16258255
4. TC Chou 2006 Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol Rev 58 621 681 10.1124/pr.58.3.10 1:CAS:528:DC%2BD28XhtVOhtLfL 16968952
5. KG Daniel D Chen B Yan QP Dou 2007 Copper-binding compounds as proteasome inhibitors and apoptosis inducers in human cancer Front Biosci 12 135 144 10.2741/2054 1:CAS:528:DC%2BD28Xht1WgsLzM 17127289
6. KG Daniel P Gupta RH Harbach WC Guida QP Dou 2004 Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells Biochem Pharmacol 67 1139 1151 10.1016/j.bcp.2003.10.031 1:CAS:528:DC%2BD2cXhvFSrsLw%3D 15006550
7. Friedberg EC, Walker GC, Siede W, Wood RD, Schultz RA, Ellenberger T (2006) DNA repair and mutagenesis, 2nd edn. American Society of Microbiology Press, Washington, DC
8. AK Holzer SB Howell 2006 The internalization and degradation of human copper transporter 1 following cisplatin exposure Cancer Res 66 10944 10952 10.1158/0008-5472.CAN-06-1710 1:CAS:528:DC%2BD2sXivVyqtrk%3D 17108132
9. AK Holzer K Katano LW Klomp SB Howell 2004 Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells Clin Cancer Res 10 6744 6749 10.1158/1078-0432.CCR-04-0748 1:CAS:528:DC%2BD2cXot1Ohsrk%3D 15475465
10. S Ishida J Lee DJ Thiele I Herskowitz 2002 Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals Proc Natl Acad Sci USA 99 14298 14302 10.1073/pnas.162491399 1:CAS:528: DC%2BD38XosF2iurs%3D 12370430
11. M Jackel P Kopf-Maier 1991 Influence of cisplatin on cell-cycle progression in xenografted human head and neck carcinomas Cancer Chemother Pharmacol 27 464 471 10.1007/BF00685161 1:STN:280:DyaK3M7ptFOjsg%3D%3D 2013116
12. DD Jandial S Farshchi-Heydari CA Larson GI Elliott WJ Wrasidlo SB Howell 2009 Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1 Clin Cancer Res 15 553 560 10.1158/1078-0432.CCR-08-2081 1:CAS:528: DC%2BD1MXlvFertg%3D%3D 19147760
13. Y Jung SJ Lippard 2007 Direct cellular responses to platinum-induced DNA damage Chem Rev 107 1387 1407 10.1021/cr068207j 1:CAS:528:DC%2BD2sXksFSgu7Y%3D 17455916
14. L Kelland 2007 The resurgence of platinum-based cancer chemotherapy Nat Rev Cancer 7 573 584 10.1038/nrc2167 1:CAS:528:DC%2BD2sXotVKru7c%3D 17625587
15. C Leroy SE Lee MB Vaze F Ochsenbien R Guerois JE Haber MC Marsolier-Kergoat 2003 PP2C phosphatases Ptc2 and Ptc3 are required for DNA checkpoint inactivation after a double-strand break Mol Cell 11 827 835 10.1016/S1097-2765(03)00058-3 1:CAS:528:DC%2BD3sXjtVWktLk%3D 12667463
16. X Liang E Reed JJ Yu 2006 Protein phosphatase 2A interacts with Chk2 and regulates phosphorylation at Thr-68 after cisplatin treatment of human ovarian cancer cells Int J Mol Med 17 703 708 1:CAS:528:DC%2BD28Xks1ChsLw%3D 16596250
17. X Lin T Okuda A Holzer SB Howell 2002 The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae Mol Pharmacol 62 1154 1159 10.1124/mol.62.5.1154 1:CAS:528:DC%2BD38XosVKisr8%3D 12391279
18. X Lu T-A Nguyen S-H Moon Y Darlington M Sommer LA Donehower 2008 The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways Cancer Metastasis Rev 27 123 135 10.1007/s10555-008-9127-x 18265945
19. J Majka PM Burgers 2003 Yeast Rad17/Mec3/Ddc1: a sliding clamp for the DNA damage checkpoint Proc Natl Acad Sci USA 100 2249 2254 10.1073/pnas. 0437148100 1:CAS:528:DC%2BD3sXitVajtLc%3D 12604797
20. EL Mamenta EE Poma WK Kaufmann DA Delmastro HL Grady SG Chaney 1994 Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines Cancer Res 54 3500 3505 1:CAS:528: DyaK2cXkslehsLc%3D 8012973
21. EG Mimnaugh MK Yunmbam Q Li P Bonvini S-G Hwang J Trepel E Reed L Neckers 2000 Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors Biochem Pharmacol 60 1343 1354 10.1016/S0006-2952(00)00455-X 1:CAS:528:DC%2BD3cXmslOjt7c%3D 11008128
22. A Motegi Y Murakawa S Takeda 2009 The vital link between the ubiquitin-proteasome pathway and DNA repair: impact on cancer therapy Cancer Lett 283 1 9 10.1016/j.canlet.2008.12.030 1:CAS:528:DC%2BD1MXoslSjt7w%3D 19201084
23. BM O'Neill SJ Szyjka ET Lis AO Bailey JR Yates 3rd OM Aparicio FE Romesberg 2007 Pph3-Psy2 is a phosphatase complex required for Rad53 dephosphorylation and replication fork restart during recovery from DNA damage Proc Natl Acad Sci USA 104 9290 9295 10.1073/pnas.0703252104 17517611
24. M Olivero T Ruggiero S Saviozzi A Rasola N Coltella S Crispi F Di Cunto R Calogero MF Di Renzo 2006 Genes regulated by hepatocyte growth factor as targets to sensitize ovarian cancer cells to cisplatin Mol Cancer Ther 5 1126 1135 10.1158/1535-7163.MCT-06-0013 1:CAS:528:DC%2BD28XltVWntb8%3D 16731744
25. R Pabla V Pawar H Zhang W Siede 2006 Characterization of checkpoint responses to DNA damage in Saccharomyces cerevisiae: basic protocols Meth Enzymol 409 101 117 10.1016/S0076-6879(05)09006-3 1:CAS:528:DC%2BD2sXmt1Giurs%3D 16793397
26. A Podlaska J McIntyre A Skoneczna E Sledziewska-Gojska 2003 The link between 20S proteasome activity and post-replication DNA repair in Saccharomyces cerevisiae Mol Microbiol 49 1321 1332 10.1046/j.1365-2958.2003.03635.x 1:CAS:528:DC%2BD3sXnslGksL4%3D 12940990
27. JP Rogers AE Beuscher IV M Flajolet T McAvoy AC Nairn AJ Olson P Greengard 2006 Discovery of protein phosphatase 2C inhibitors by virtual screening J Med Chem 49 1658 1667 10.1021/jm051033y 1:CAS:528: DC%2BD28XhtlSrt7Y%3D 16509582
28. DJ Stewart 2007 Mechanisms of resistance to cisplatin and carboplatin Crit Rev Oncol Hematol 63 12 31 10.1016/j.critrevonc.2007.02.001 17336087
29. J Takezawa Y Ishimi K Yamada 2008 Proteasome inhibitors remarkably prevent translesion replication in cancer cells but not normal cells Cancer Sci 99 863 871 10.1111/j.1349-7006.2008.00764.x 1:CAS:528:DC%2BD1cXlslCrsb8%3D 18294277
30. PM Voorhees RZ Orlowski 2006 The proteasome and proteasome inhibitors in cancer therapy Annu Rev Pharmacol Toxicol 46 189 213 10.1146/annurev.pharmtox. 46.120604.141300 1:CAS:528:DC%2BD28XisFKltLc%3D 16402903
31. H Zhang W Siede 2003 Validation of a novel assay for checkpoint responses: characterization of camptothecin derivatives in Saccharomyces cerevisiae Mutat Res 527 37 48 1:CAS:528:DC%2BD3sXkt1ymtb8%3D 12787912
32. H Zhang Z Zhu G Vidanes D Mbangkollo Y Liu W Siede 2001 Characterization of DNA damage-stimulated self-interaction of Saccharomyces cerevisiae checkpoint protein Rad17p J Biol Chem 276 26715 26723 10.1074/jbc.M103682200 1:CAS:528:DC%2BD3MXlsVKnurg%3D 11356855